Skip to content

KLRS KLRS Total Equity

Total Equity at other companies

Eli Lilly logo
Eli LillyLLY
$31.2B+97.9%
Merck & Co. logo
Merck & Co.MRK
$45.88B-5.1%
Amgen logo
AmgenAMGN
$9.19B+48.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$230.47M-22.8%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$581.57M+119%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's total equity?
KLRS (KLRS) reported total equity of $68.56M in Q1 2026.
How has KLRS's total equity changed year-over-year?
KLRS's total equity increased by 7.3% year-over-year, from $63.87M to $68.56M.
What is the long-term trend for KLRS's total equity?
Over 5 years (2020 to 2025), KLRS's total equity has grown at a -25.9% compound annual growth rate (CAGR), from $353.06M to $78.81M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.